The efficacy of combining the PD-L1 inhibitor durvalumab with the CTLA-4 inhibitor tremelimumab was assessed in a phase I trial (NCT01938612) involving an Asian population with advanced CCA. The gene discussed is CTLA4; the disease is cholangiocarcinoma.